Introduction
The muscarinic acetylcholine receptors (mAChRs) belong to the rhodopsin-like (Class A) family of G protein-coupled receptors (GPCRs). Five distinct mAChR subtypes (denoted M 1 -M 5 ) exist and exhibit a widespread distribution throughout the central nervous system (CNS) and peripheral organs (Caulfield 1993; Nathanson 2008; Kruse et al., 2014) . The M 1 , M 3 and M 5 mAChRs preferentially couple to G q/11 proteins, whereas the M 2 and M 4 mAChRs preferentially couple to G i/o proteins. However, an ever-growing array of additional signalling pathways, including those not necessarily mediated by G proteins, has also been linked to mAChR activation (Lanzafame et al., 2003) .
The M 1 mAChR is highly expressed in the cerebral cortex, hippocampus, striatum and thalamus (Cortés et al., 1986; 1987; Elhert and Tran, 1990) ; regions vital for memory, cognitive and locomotor functions. Therefore, the M 1 mAChR has long been implicated in learning and memory, and remains a potential target for the treatment of Alzheimer's disease and schizophrenia (Caulfield 1993; Langmead et al., 2008) . A role for the M 1 mAChR in treating the cognitive impairment in both of these diseases is further supported by the decrease in M 1 mAChR expression in the pre-frontal cortex in brains from schizophrenic patients (Melancon et al., 2013; Conn et al., 2009) . Improved cognition, learning and memory were observed in preclinical studies using the M 1 /M 4 -preferring orthosteric agonist, xanomeline (Xan), which were attenuated in M 1 mAChR knockout (KO) mice (Bymaster et al., 2003) , whereas memory deficits have been observed upon administration of mAChR antagonists or M 1 mAChR KO in mice (Sauerberg et al., 1992; Wess 2004; Davie et al., 2014) . Importantly, Xan demonstrated clinical efficacy, particularly in treating psychosis and cognitive decline in clinical trials of Alzheimer's disease and schizophrenia. Despite this, MOL #111633 5 Xan was not pursued further due to unacceptable off-target effects, largely attributed to a lack of mAChR subtype selectivity (Bodick et al., 1997; Shekar et al., 2008) . Encouragingly, the mAChRs possess spatially distinct allosteric sites, which can be selectively targeted (Kruse et al., 2013; 2014) . Recently, benzyl quinolone carboxylic acid (BQCA) was described as the first highly selective positive allosteric modulator (PAM) of the M 1 mAChR, with preclinical efficacy in animal models of cognition (Ma et al., 2009 ) and has served as a major impetus for new discovery efforts (Kruse et al., 2014) . However, significant challenges and unanswered questions remain regarding the optimal type of allosteric ligand for successful progression through preclinical studies to man. For instance, allosteric modulators can display complex behaviours such as "probe dependence", where the magnitude and direction of an allosteric effect for the modulator can change depending on which orthosteric ligand is used as a probe for receptor function (Kenakin 2005) . Another example is "biased modulation"; the ability of different allosteric ligands to engender unique receptor conformations, whereby certain signalling pathways are differentially modulated relative to others (Kenakin and Christopoulos 2013; Christopoulos 2014 ).
The simplest mechanism that explains allostery is the classic Monod-Wyman-Changeux (MWC) model (Monod et al., 1965) , which predicts that probe dependence arises as a function of the efficacy of the orthosteric ligand, and that biased modulation cannot occur without the existence of additional active states (Canals et al., 2011; Changeux and Christopoulos 2016) . A characterization of BQCA at the M 1 mAChR revealed that BQCA indeed behaves in a manner generally consistent with a two-state MWC mechanism (Canals et al., 2012; Ehlert and Griffin, 2014) . However, this is not always the case with other mAChR modulators (e.g. Valant et al., 2012) , and thus detailed molecular pharmacological MOL #111633 6 characterisation is a necessary first step in understanding the mechanism of action of any new allosteric ligands. Although BQCA was a major breakthrough in terms of proof of concept, it possesses a very low affinity for the receptor, and additional liabilities that precluded it from further clinical development (Canals et al., 2011; Davoren et al., 2016) . Thus, there remains an ongoing need for the discovery of new M 1 mAChR PAMs.
Our laboratory recently identified a series of novel M 1 mAChR PAMs with 4-phenylpyridine-2-one and 6-phenylpyrimidin-one scaffolds that are distinct from BQCA (Mistry et al., 2016) . However, a detailed mechanistic evaluation of their pharmacological properties has not been undertaken. Thus, the aim of this study was to characterise exemplar molecules from this series of PAMs and compare their behaviours to BQCA, particularly with regards to mechanisms underlying probe dependence and the potential for biased modulation. We found that, despite possessing a chemically distinct scaffold, the novel PAMs generally behave in a manner akin to that of BQCA. 
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Materials and Methods
Materials
, and 3-(2-hydroxycyclohexyl)-6-(2-((4-
(1-methyl-1H-pyrazol-4-yl)-benzyl)oxy)phenyl)pyrimidin-4(3H)-one (MIPS1780) were synthesized in house (Mistry et al. 2016) . Xanomeline was a generous gift from Dr. Christian
Felder (Eli Lilly, USA). Coelenterazine h was purchased from Nanolight Technologies (Pinetop, AZ, USA). The YFP--arrestin-2 construct was a gift from Dr. Marc Caron (Duke University). The M 1 -Rluc8 constructs were generated in-house as described previously (Yeatman et al. 2014) . All other chemicals were purchased from Sigma-Aldrich (St Louis, MO). Data analysis: All data analysis was performed using GraphPad Prism v.7.02. Concentration response curves were fitted using a three parameter logistic non-linear regression model to derive potency (pEC 50 ) and efficacy (E max ) parameters.
IP 1 alkylation experiments were globally fitted to an operational model of agonism (Black and Leff, 1983) to determine orthosteric agonist equilibrium dissociation constant (functional affinity; K A ) and the agonist operational efficacy (τ), which takes both receptor density and stimulus-response coupling efficiency into account: 
Where basal is the response in the presence of vehicle, [B] is the concentration of allosteric ligand and K B represents its equilibrium dissociation constants.  B represents an operational measure of allosteric ligand efficacy,  denotes the binding cooperativity between orthosteric MOL #111633 11 and allosteric ligand, whereas β denotes a scaling factor that quantifies the allosteric effect of the modulator on orthosteric ligand efficacy. This model assumes that all orthosteric ligands are either full agonists at the receptor on both the absence/presence of modulator and/or there is no efficacy modulation (i.e., β = 1). As shown in the Results, one or both of these assumptions were met with the various orthosteric ligands used, and thus the β parameter was constrained to 1. All other parameters are as defined in equation 1.
Also as shown in the Results, the ERK1/2 responses at the M 1 mAChR were bell-shaped.
For the purposes of fitting the allosteric operational model to the data, the points defining the decreasing phases of the curves (i.e., those beyond 10μM of agonist) were removed from each curve to allow convergence of the allosteric operational model (Eqn 2).
All affinity, potency and cooperativity values were estimated as logarithms (Christopoulos 1998 ) and statistical comparisons between values were by one-way analysis of variance with either a Neuman-Kewls or Dunnett's multiple comparison test. A value of p<0.05 was considered statistically significant.
Results:
Novel 4-phenylpyridin-2-one and 6-phenylpyrimidin-4-one based compounds are selective for the M 1 mAChR over other mAChR subtypes.
Recent work from our laboratory identified a novel series of 4-phenylpyridin-2-one and 6-phenylpyrimidin-4-one M 1 mAChR PAMs ( Figure 1A ) that represent a different chemical scaffold to BQCA and related analogues (Mistry et al., 2016) . When assessed for effects on the IP 1 signalling pathway, our preliminary pharmacological characterization indicated that MIPS1674 was an allosteric agonist with minimal PAM activity against ACh, MIPS1745 was a "pure" PAM of ACh with no direct allosteric agonism, whereas MIPS1780 behaved as a mixed PAM-agonist in modulating ACh function (akin to responses observed with BQCA).
Thus, the fact that these three PAMs potentially exhibited three different "allosteric phenotypes" (Mistry et al., 2016) formed the basis for selecting them for further pharmacological evaluation. These compounds were initially tested to ensure they were selective for the M 1 mAChR over other mAChR subtypes using an ERK1/2 phosphorylation assay. Figure The next aim of this study was to investigate the potential for probe dependence of the novel allosteric modulators and the contribution of different degrees of intrinsic agonist efficacy to the phenomenon. mAChR agonists of variable efficacies were selected to use as orthosteric probes. Specifically, the endogenous agonist, ACh, was chosen as this represents the physiologically relevant mAChR neurotransmitter against which all putative allosteric ligands need to be tested. Oxotremorine-M (Oxo-M) was chosen, as this is commonly used as a high efficacy mAChR agonist in numerous in vitro and in vivo studies (e.g., Valant et al., 2012) . Iperoxo (Ixo) was chosen as it remains the highest efficacy mAChR agonist identified to date (Langmead and Christopoulos 2013; Schrage et al., 2013) , while Xanomeline (Xan) was chosen because it is a partial agonist, has a functional preference for M 1 and M 4 mAChRs over other mAChR subtypes, and had progressed into clinical trials on the basis of this selectivity (see Introduction).
Initially, the affinities and intrinsic efficacies of the orthosteric agonists were characterised using an assay of M 1 mAChR-mediated IP 1 accumulation, a classic signalling pathway downstream of activation of G q/11 -linked receptors. All orthosteric agonists increased IP 1 accumulation in our FlpInCHO-hM 1 cell line in a concentration-dependent manner. ACh, Ixo and Oxo-M were all full agonists in this assay, whereas, Xan was a weak partial agonist (with an E max approx. 30% of that observed for ACh; Table 1 ). The functional affinities (pK A ) and operational efficacies (τ) of the othosteric probes were also determined at the M 1 mAChR by treating the cells with the irreversible alkylating agent, phenoxybenzamine (PBZ), to occlude the orthosteric site (Furchgott 1966 (Figure 2 ). Small, albeit significant (p < 0.05) effects were observed on the potency of Ixo, where a 0.5-1 log unit shift was observed when treated with the higher concentrations of PBZ (1μM and 10μM, respectively). Overall, this suggests that this system has a low level of receptor reserve for this pathway in our cell line. The family of curves for each agonist was globally fitted to an operational model of agonism (Eqn 1), with the efficacy parameter, τ, allowed to vary for each curve (since τ is determined by receptor density) but all other parameters constrained to be shared. The resulting agonist functional affinity values, determined as equilibrium dissociation constants (K A ), and the τ values for the control curve (absence of PBZ) are listed in Table 1 , which confirms a rank order of efficacies of Ixo ( = 10.7) > Oxo-M ( = 4.6) > ACh ( = 3.6) >> Xan ( = 0.5). In addition to the efficacy estimates, the agonist K A values revealed that Xan and Ixo had significantly higher affinities for the M 1 mAChR than ACh or Oxo-M (p < 0.05, Table 1 ).
BQCA exhibits probe dependence with different orthosteric agonists at the M 1 mAChR.
As outlined in the Introduction, the simplest mechanism to explain probe dependence is the classic two-state MWC model. This model predicts that the effect of a PAM is to positively modulate the activity of an orthosteric agonist but negatively modulate the activity of an orthosteric antagonist (inverse agonist) in a manner that tracks with the intrinsic efficacy of the orthosteric ligand, i.e., higher efficacy agonists will be potentiated to a greater degree than lower efficacy agonists; the model does not predict pathway-biased modulation without incorporation of additional receptor states (Canals et al., 2012; Christopoulos 2014; Ehlert and Griffin, 2014 (Mistry et al., 2016) . This constraint was used to aid model convergence, and was selected because it is the binding affinity value determined from full interaction equilibrium binding assays between ACh, BQCA and 3 H-NMS in the same cell line used for this study (Mistry et al., 2016) . The resulting parameter values are listed in Table 2 . From these experiments and resulting analysis, two important findings were made. First, the degree of potentiation of each agonist by BQCA was variable (α values), clearly indicating probe dependence. Second, it was of note that the allosteric modulation was manifested only on the potency of each agonist (i.e., changing the EC 50 and not on the E max ). Given that the prior alkylation studies (Figure 2 , Table 1) confirmed that this assay has minimal receptor reserve, any potential allosteric effects on agonist signalling efficacy would have been revealed as increases in the E max , at least for the lower efficacy agonists. The fact that this was not observed in any instance indicates that BQCA modulates only the affinity of the orthosteric agonists, not their efficacy. As such, the co-operativity estimates (αβ) from the operational model analysis are measures of "pure" affinity modulation (α).
As summarized in Table 2 and Figure 3 , BQCA potentiated ACh (α ACh = 40) and Ixo (α Ixo = 25) to the greatest extent; Oxo-M (α OxoM = 10) was potentiated to a lesser extent, although realistically these differences in potentiation were marginal, showing only a four-fold difference at most. BQCA showed no modulation, i.e., was a neutral allosteric ligand (NAL), with respect to the weakest agonist, Xan. On its own, BQCA showed very little to no intrinsic efficacy (τ B = 0.2-0.8), confirming previous findings (Yeatman et al., 2014) .
Effects of novel M 1 mAChR PAMs on ACh-mediated IP 1 accumulation
We next investigated the effects of each of the two 4-phenylpyridin-2-one-based (MIPS1674 and MIPS1745) and the 6-phenylpyrimidin-4-one-based ( showed a substantially lower degree of potentiation. Interestingly, we also noted a number of differences in the behaviour of the novel PAMs compared to our initial preliminary characterization (Mistry et al., 2016) . For instance, MIPS1674 showed modest modulatory effects on ACh but little to no direct allosteric agonism. MIPS1745 was not a "pure" PAM as originally described by Mistry et al., (2016) but rather, a PAM-agonist ( B = 1.2) like MIPS1780 ( B = 5.9). Although the same cellular background was used for both the current study and that of Mistry et al. (2016) , the IP 1 accumulation assay protocol was performed under different conditions (adherent vs suspended cells), which may account for the differences observed.
Investigation of mechanisms of probe dependence mediated by MIPS1674, MIPS1780 and MIPS1745 with different agonists at the M 1 mAChR.
To determine whether the novel PAMs exhibit probe dependence, the interaction experiments were extended to include the effects of other mAChR agonists on IP 1 accumulation. As observed with BQCA, no effect of the novel PAMs on the maximal response of the various agonists used in this study was detected ( Figure 5 ), again suggesting that any allosteric modulation by the novel M 1 mAChR PAMs is manifested at the level of agonist binding affinity only. Subsequent analysis of these data by an operational model of allostery (Eqn 2) provided co-operativity estimates for individual modulators with each agonist (Table 2; summarized Figure 6B -D). MIPS1674 potentiated the ACh response (α = 11) to a greater extent than Oxo-M (α = 5) and significantly more than that seen with Ixo (α = 3), suggesting that this modulator exhibits probe dependence, modulating the endogenous agonist ACh to a greater extent than the higher potency agonist Ixo. MIPS1745 and MIPS1780 behaved like BQCA, in that they potentiated ACh, Ixo and Oxo-M to similar extents ( Figure 6 ). Xan was weakly modulated (α = 19) by the most robust PAM, MIPS1780, although the co-operativity estimate was associated with a larger error than for the other agonists. No modulation of the Xan response was observed with any of the other allosteric modulators tested, again consistent with a NAL effect. Nonetheless, the overall findings are broadly consistent with those seen with BQCA, that is, the higher efficacy agonists were modulated to a greater extent than the lowest efficacy agonist (Xan). For a weak PAM, i.e., MIPS1674, the overall degree of positive modulation was low irrespective of the agonist ( Figure 6B ), whereas for the most robust PAMs, i.e., MIPS1780 and MIPS1745, the magnitude of the positive cooperativity noted with ACh, Oxo-M or Ixo ( Figure 6 ) was in the range observed with the prototypical PAM, BQCA.
Novel M 1 PAMs show minimal evidence of biased modulation
It is not uncommon to see different overall degrees of functional PAM effects of GPCR modulators in cell-based assays. Although this may be taken as presumptive evidence of "pathway biased modulation", a simpler explanation is that assays characterized by stronger stimulus-response coupling (e.g., more amplified responses), may be more prone to manifesting stronger PAM effects due to the potential greater sensitivity of PAM-agonism being unmasked in such assays (Keov et al., 2011) . It is only when this property is not a contributor that true pathway bias can be considered. Previously, BQCA showed no bias,
relative to ACh, when tested against carbachol in a range of signalling assays (Canals et al., 2012; Yeatman et al., 2014) . To confirm this general effect we used the endogenous agonist, ACh, and the PAM, BQCA, as comparators for the effects of the new chemotypes. We first examined the effect of BQCA on the endogenous agonist, ACh, toward 3 signalling pathways; ERK1/2 phosphorylation as a representative of an efficiently coupled pathway; IP 1 accumulation and β-arrestin-2 recruitment (βarr2) as weakly coupled pathways. In Figure   7A -C, the family of curves were globally fitted to the operational model of allostery (Eqn 2), constraining the pK B values to the binding affinity values determined by Mistry et al., (2016), as described above, and with the resulting parameters shown in Table 3 . The rank order of co-operativity for the pathways was ERK1/2 (α = 871) >> IP 1 (α = 40) ≥ βarr2 (α = 23).
The novel 4-phenylpyridin-2-ones and 6-phenylpyrimidin-4-one were also tested on the same three pathways and the data sets were analysed in the same manner as BQCA (described above). MIPS1745 and MIPS1780 had the greatest efficacy (τ B ) toward the more amplified Figure 8 and Figure 9 ). The rank order of co-operativity was ERK1/2>IP 1 >βarr2, thus as observed with BQCA, MIPS1745 and MIPS1780 were PAMs toward all pathways, and the potentiation of the responses tracked with stimulus coupling.
When the MIPS1674 data were analysed using the operational model of allostery (Eqn 2), it did not appear to modulate βarr2 recruitment, but did weakly modulate the other signalling pathways. As shown in Figure 8 , Figure 9 and Table 3 , MIPS1674 had weak efficacy toward the ERK1/2 (τ B = 1.4) pathway and no efficacy for the IP 1 or βarr2 pathways. MIPS1674
weakly modulated ACh activity toward ERK1/2 and IP 1 , with a rank order of co-operativity of IP 1 (α = 12) > ERK1/2 (α = 4). By visual inspection of the concentration response curves, MIPS1674 acted as a "pure" PAM towards IP 1 , is an allosteric agonist with minimal PAM activity toward ERK1/2, and was a NAL toward βarr2. Although, these results may suggest that MIPS1674 has the potential to be a biased modulator at the M 1 mAChR, a more parsimonious explanation is that the low level of receptor expression and differences in stimulus-response coupling the IP 1 and β-arrestin recruitment pathway resulted in an insufficient response window to reveal any potentiation of the ACh β-arrestin recruitment response, particularly since MIPS1674 was the least effective PAM of the new series.
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Discussion:
The discovery of BQCA ushered in a new era of drug discovery for the M 1 mAChR, particularly with regards to novel potential modalities for treatment of cognitive deficits (Ma et al., 2009; Davie et al., 2013) . Subsequent detailed pharmacological characterization of BQCA also revealed key features consistent with the simplest mechanism of receptor allostery, namely the two-state MWC model (Canals et al., 2012) , and thus provided a guide for the subsequent pharmacological assessment of novel allosteric modulators at both mAChRs and other GPCRs. This is relevant to the current study, which investigated novel PAMs chemically distinct from BQCA. Preliminary findings with the 4-phenylpyridin-2-ones and 6-phenyl-4-ones suggested that they may have diverse pharmacological phenotypes, reflective of more complex, and potentially biased, allosteric behaviours (Mistry et al., 2016) .
The main findings of this study indicate that the novel M 1 mAChR PAMs display probe dependence at the M 1 mAChR but minimal evidence of biased modulation. These findings have implications for future elaboration of this new chemical series, with an ultimate aim towards producing molecules that are more tractable to "drug-like" behaviour than BQCA.
As indicated previously, the key prediction of a two-state MWC model is that the degree of allosteric modulation will "track" with the efficacy of the orthosteric probe, i.e., if an allosteric ligand prefers an active receptor state, it follows that: (i) it will be a PAM of agonists and a NAM (negative allosteric modulator) of inverse agonists (and vice versa for modulators that prefer the inactive state); (ii) that higher efficacy agonists will be potentiated by PAMs to a greater extent than lower efficacy agonists; (iii), there should be no pathwaybiased modulation (Canals et al., 2011; . Any divergence from this behaviour could suggest a more complex mode of action involving multiple receptor states. However, since cellular stimulus-response coupling will have an effect on observed agonism (Keov et al., MOL #111633 21 2011) , it is vital to account for this property and, where possible, apply approaches that divorce the host system-dependence of allostery and agonism from the underlying molecular parameters that govern these phenomena. The different degree of maximal agonist responsiveness observed in the IP 1 accumulation assays indicated that our recombinant cell line likely exhibited a very low receptor reserve, which was confirmed by receptor alkylation experiments and application of an operational model of agonism. However, it should be noted that a detailed analysis of the predictions of the MWC model in operational terms by Ehlert and Griffin (2014) found that the only aspects of the stimulus-response transduction mechanism that should affect observed modulation (αβ values) are receptor-proximal events, e.g., receptor or transducer stoichiometry. Moreover, low efficacy agonists may be expected to show changes in the maximal response (Ehlert and Griffin, 2014), which was not observed in our current study (e.g., with Xan). It is possible that this reflects a divergence from an MWC mechanism or, more parsimoniously, that Xan selects for a very low activity state such that any effects on its signaling efficacy simply cannot be observed over the concentration range of PAMs utilized in our study.
The low receptor reserve of the FlpInCHO-hM 1 cell system proved both advantageous and, to some extent, disadvantageous depending on the question that was asked. An advantage of the low receptor reserve system is that the lack of effect of BQCA and the novel PAMs on agonist E max , while modulating potency, could only be explained if the modulators mediated their effects purely through changing agonist affinity, as efficacy effects would manifest as a change in E max , particularly for Xan. This allowed the application of a simplified operational model of allostery that quantified the global cooperativity of the PAMs (Aurelio et al., 2009 ).
Although differences were observed in the behaviours and operational model parameter estimates in our IP 1 accumulation studies versus those performed by Mistry et al. (2016) , this MOL #111633 22 likely reflected variances in IP 1 assay protocol, as well as potential variability in cell background due to cell passage. Irrespective, our analysis suggested that all novel PAMs, like BQCA, tended to potentiate higher efficacy agonists to a greater extent than the low efficacy agonist, Xan.
A possible disadvantage of the low receptor reserve displayed by our cell line was evident in the studies of allosteric modulation between different pathways linked to M 1 mAChR activation. Ideally, the choice of pathways was designed to reflect events that are generally considered substantially proximal (e.g., β-arrestin 2 recruitment) or substantially downstream (e.g., pERK1/2) from receptor activation, with IP 1 accumulation representing a pathway that would display a degree of stimulus-response coupling somewhere between the two (Lanzafame et al., 2003; Canals et al., 2012; Abdul-Ridha et al., 2014) . This, in turn, would allow for a clear delineation of whether the modulation between a given agonist-modulator pair tracked with the degree of stimulus-response coupling or differed. The former scenario was generally the case when comparing the effects of the PAMs on ACh-mediated pERK1/2 to either β-arrestin 2 recruitment or IP 1 accumulation, but more equivocal when comparing ACh-mediated β-arrestin 2 recruitment to IP 1 accumulation. However, if the degree of receptor coupling efficiency to the IP 1 pathway and β-arrestin 2 recruitment pathways was similar, due to low receptor reserve, then the MWC model would predict similar degrees of potentiation at each pathway, and it is thus not surprising that the PAM effects on ACh at β-arrestin 2 recruitment or IP 1 accumulation did not display the degree of separation seen when compared to the pERK1/2 assays.
It is now established that allosteric ligands have the potential to engender multiple biologically active GPCR states (Kenakin et al., 2012; Davey et al., 2012; Wislar et al., 2007) . As a consequence, deviations from simple MWC-governed allosteric behaviour in terms of probe dependence and pathway bias have been observed at multiple GPCRs, emphasising the importance of routinely investigating these therapeutically relevant paradigms whenever characterising novel ligands (Christopoulos 2014; Price et al., 2005; Valant et al., 2012) . For example, at the M 2 mAChR, the allosteric modulator, LY2033298, positively modulates the binding affinity of multiple orthosteric agonists, but has either positive or negative allosteric effects on the signalling efficacy and signalling pathway of the same agonists. Thus, functionally, LY2033298 is a PAM of Oxo-M, a NAL of ACh, and a NAM of Xan . This type of probe dependence cannot be reconciled within a two-state mechanism, and is clearly suggestive of biased modulation involving multiple receptor active states (Christopoulos 2014) . Given that surrogate orthosteric probes are often used preclinically in vitro or in vivo, due to the metabolic instability of the endogenous GPCR agonist (Leach et al., 2010) , or that multiple endogenous ligands and their metabolites exist for a single GPCR (van der Westhuizen et al., 2015 , Wootten et al., 2012 , a lack of appreciation of the differences underlying probe dependence as a function of intrinsic efficacy (i.e., simple two-state MWC model) or probe dependence as a function of different conformational states (i.e., biased modulation), can lead to misinterpretation of preclinical data and thus inappropriate selection of potential allosteric drug candidates for further optimization and development.
In conclusion, despite possessing a chemically distinct scaffold, the similar molecular fingerprints of the 4-phenylpyridine-2-one and 6-phenylpyrimidin-4-one PAMs to that of BQCA suggests a similar molecular mechanism of action, and is consistent with a common binding site. This site is proposed to overlap with the "common" allosteric binding pocket Table 2 . Data are mean±SEM of 6 independent experiments with repeats in duplicate. Table 3 ). Data are mean±SEM of 4-8 independent experiments with repeats in duplicate. Data were analysed by one-way ANOVA, with Neuman-Kewls multiple comparisons tests, where *p<0.05 was considered to be significantly different.
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Tables: Table 1 Results of the statistical tests are shown in Figure 9 . Mistry et al., (2016) , and constrained as a constant in the current analysis.
c Logarithm of the cooperativity between ACh and the allosteric modulator, derived using Eqn 2.
